Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ionis Pharmceuticals Inc. is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The case is assigned to 1 distinct examiner, DACE DENITO, ALEXANDRA GERALDINE, who is also the busiest examiner for the company. The presence of 1 pending action indicates the current scale of the company's active prosecution.
The activity is concentrated in 1 distinct art unit. DACE DENITO, ALEXANDRA GERALDINE is the busiest examiner for the company, with 1 pending action. This concentration in 1 distinct art unit suggests a specific technical focus. Practitioners should note that the company's current interactions with the patent office are centralized under this 1 distinct examiner. The outcome of the pending office action will define the company's immediate success in the Biotechnology & Pharmaceuticals field.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245609 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION | DACE DENITO, ALEXANDRA GERALDINE | — |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18245609 | PHARMACEUTICAL COMPOSITIONS COMPRISING AN ANTISENSE OLIGONUCLEOTIDE FOR ORAL ADMINISTRATION | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Mar 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIonis Pharmceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexandra Geraldine Dace Denito has the most, with 1 of Ionis Pharmceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
